Abstract: The present disclosure relates to methods for treating Lupus Nephritis (LN) using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating LN patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Abstract: The present disclosure relates to methods for treating patients having autoimmune diseases, e.g., methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS), using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. Also disclosed herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. The present disclosure also provides medicaments, pharmaceutical formulations, dosage forms, and kits for use in the disclosed methods.

Abstract: The invention comprises a computer-implemented method comprising the steps of providing a medical dataset with data of a plurality of patients and pertaining to at least one disease, associating the data in the dataset with corresponding parts of the human body, to which the data pertains, displaying, on a display device, a graphical representation of the human body (1) or of a part of the human body, displaying, on the display device, a plurality of activatable buttons (2) associated with different parts of said graphical representation (1), receiving a user input activating one of the plurality of activatable buttons (2), and based on the activation, displaying, on the display device, a graphical representation of the data (4) associated with that part of the human body, to which the activatable button (2) activated by the user input pertains.

Abstract: The present invention provides methods for predicting the likelihood of development of systemic lupus erythematosus (SLE) in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding Fc?RIIB. The invention also provides isolated nucleic acids encoding Fc?RIIB polymorphisms, nucleic acid probes that hybridize to polymorphic positions and kits for the prediction of SLE status.

Abstract: The present invention provides methods for predicting the likelihood of development of systemic lupus erythematosus (SLE) in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding Fc?RIIB. The invention also provides isolated nucleic acids encoding Fc?RIIB polymorphisms, nucleic acid probes that hybridize to polymorphic positions and kits for the prediction of SLE status.

Abstract: The present invention provides methods for predicting the likelihood of development of systemic lupus erythematosus (SLE) in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding Fc&ggr;RIIB. The invention also provides isolated nucleic acids encoding Fc&ggr;RIIB polymorphisms, nucleic acid probes that hybridize to polymorphic positions and kits for the prediction of SLE status.